Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2018

View Archived Issues

FDA clears IND application for a phase I study of OBI-888

Transgene begins phase I study of T-101 for HBV in China

Life Science Institute announces beginning of exploratory study of CL-2020

Sandoz enters biosimilar partnership with Biocon

Program to study radezolid for bacterial vaginosis begins

Pandion Therapeutics announces completion of series A financing

Evaluation of [18F]MK-6240 for tau pathology imaging shows promise

Japanese approval for Lynparza as maintenance therapy in advanced ovarian cancer

Inception 4 patents novel HTRA1 inhibitors

Orion divulges alpha2C adrenoceptor antagonists

Bristol-Myers Squibb identifies new TLR7/8/9 antagonists

Zhejiang Hisun Pharmaceutical presents new SERAMs for cancer

Pfizer's Besponsa approved in Japan for ALL

Novel mutant IDH1 inhibitors presented by HHS

OPC-64005 studied in phase II trial for utility in adult ADHD

Janssen initiates phase I trial of JNJ-63733657 in healthy subjects and those with Alzheimer's

Fucoidans tested in combination with chemotherapy in cancer models in vivo

Eisai licenses ex-Japan rights for E-7046 to Adlai Nortye

Elobixibat approved in Japan for chronic constipation

Rexulti tablets approved in Japan for schizophrenia

Tecentriq approved in Japan for advanced NSCLC

European Commission approves bevacizumab biosimilar Mvasi

OncoSec Medical reports preliminary data from biomarker study of ImmunoPulse IL-12

FDA awards rare pediatric disease designation to arimoclomol for Niemann-Pick disease Type C

Japanese authorities approve Sirturo for tuberculosis

Disruption of FUNDC1 function tied to heart failure

CXCR4, a therapeutic target for inhibiting ovarian cancer progression

Fasenra receives approval in Japan for bronchial asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...